Actively Recruiting
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
Led by The University of Texas at Dallas · Updated on 2025-08-14
100
Participants Needed
1
Research Sites
193 weeks
Total Duration
On this page
Sponsors
T
The University of Texas at Dallas
Lead Sponsor
U
University of Texas Southwestern Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in multiple sclerosis patients. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures. Additionally, the study will examine the degree to which baseline assessments of cognition and concussion history predict responses to treatment over time, both on assessments administered within the intervention period and at follow-up.
CONDITIONS
Official Title
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with relapsing-remitting multiple sclerosis (RRMS)
- Memory retrieval deficit based on neuropsychological testing done in our lab
- Must be fluent in speaking and reading English.
You will not qualify if you...
- Relapse or acute MS exacerbation or a course of steroids in the two months preceding the testing
- Participants using benzodiazepines must have been on a stable dose for at least two months
- Potentially confounding psychological or neurological disorders, including dementia, epilepsy, severe traumatic brain injury, brain tumor, drug abuse, stroke, blood vessel abnormalities in the brain, Parkinson's disease, and Huntington's disease
- Inability to give informed consent
- Cranial implants
- Skull defects that affect tDCS administration
- Use of medications that interact with or potentially interact with tDCS effects, including anti-convulsants, L-dopa, carbamazepine, sulpiride, pergolide, lorazepam, rivastigmine, dextromethorphan, D-cycloserine, flunarizine, ropinirole, and stimulants (dextroamphetamine/amphetamine/modafinil/armodafinil) which must be stopped during enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Texas at Dallas
Richardson, Texas, United States, 75080
Actively Recruiting
Research Team
A
Ashna Adhikari, MS
CONTACT
J
Jill Ritter, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here